• Home
  • News

Sichenzia Ross Ference Carmel LLP represents Lexaria Bioscience Corp. in $5 Million Registered Direct Offering and Concurrent Private Placement

lexaria bioscience logo

Press Release – New York, NY – October 15, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, in a $5 million registered direct offering and private placement priced at-the-market under Nasdaq rules. Gross proceeds to the company will be approximately $5 million.  

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The SRFC team was led by partners Gregory Sichenzia and Avital Perlman and associates Rohini Sud and Benasz Hansotia